Statins in coronary artery bypass grafting surgery: lipid lowering and beyond

References

• Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann. Int. Med.152(2), 69–77 (2010).
   PubMed Web of Science ®Google Scholar
• Afilalo J, Duque G, Steele R, Jukema JW, De Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol.51(1), 37–45 (2008).
   PubMed Web of Science ®Google Scholar
• Zeymer U, Junger C, Zahn R et al. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr. Med. Res. Opin.27(8), 1563–1570 (2011).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation106(3), 388–391 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation116(7), e148–e304 (2007).
   PubMed Web of Science ®Google Scholar
• Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation110(14), e340–e437 (2004).
   PubMedGoogle Scholar
• Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation118(18), 1785–1792 (2008).
   PubMed Web of Science ®Google Scholar
• Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J. Am. Coll. Cardiol.56(14), 1099–1109 (2010).
   PubMed Web of Science ®Google Scholar
• No authors listed. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N. Engl. J. Med.336(3), 153–162 (1997).
   PubMed Web of Science ®Google Scholar
• Shah SJ, Waters DD, Barter P et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J. Am. Coll. Cardiol.51(20), 1938–1943 (2008).
   PubMed Web of Science ®Google Scholar
• Domanski M, Tian X, Fleg J et al. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (post CABG) trial. Am. J. Cardiol.102(8), 1023–1027 (2008).
   Google Scholar
• Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation111(18), 2356–2363 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharmaceut. Des.15(5), 467–478 (2009).
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Leeson P et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation124(3), 335–345 (2011).
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Tousoulis D et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation122(11 Suppl.), S66–S73 (2010).
   PubMed Web of Science ®Google Scholar
• Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis188(1), 51–58 (2006).
   PubMedGoogle Scholar
• Ortego M, Bustos C, Hernandez-Presa MA et al. Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis147(2), 253–261 (1999).
   PubMed Web of Science ®Google Scholar
• Yang Z, Kozai T, Van Der Loo B et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll.Cardiol.36(5), 1691–1697 (2000).
   PubMed Web of Science ®Google Scholar
• Obi C, Wysokinski W, Karnicki K, Owen WG, Mcbane RD 2nd. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscl. Thromb. Vasc. Biol.29(9), 1271–1276 (2009).
   PubMed Web of Science ®Google Scholar
• Puccetti L, Santilli F, Pasqui AL et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis214(1), 122–128 (2011).
   PubMed Web of Science ®Google Scholar
• Porter KE, Turner NA. Statins and myocardial remodelling: cell and molecular pathways. Expert Rev. Mol. Med.13, e22 (2011).
   Web of Science ®Google Scholar
• Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study. Circulation114(14), 1455–1461 (2006).
   PubMed Web of Science ®Google Scholar
• Xu Q, Guan YQ, Zhang D, Su GH. The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials. Curr. Med. Res. Opin.27(9), 1771–1779 (2011).
   PubMed Web of Science ®Google Scholar
• Kim YM, Guzik TJ, Zhang YH et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res.97(7), 629–636 (2005).
   PubMed Web of Science ®Google Scholar
• Antoniades C, Demosthenous M, Reilly S et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery: effects of short-term preoperative statin treatment. J. Am. Coll. Cardiol. (2011) (In Press).
   Google Scholar